Intellia Therapeutics (NTLA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.80
- Estimate
- -$0.79
- Surprise
- -1.9%
- Revenue (period 2026-06-30)
- $7.7M
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
Intellia Therapeutics (NTLA) reported a wider loss than forecast — diluted EPS of -$0.80 against the -$0.79 estimate (a 1.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates NTLA Sell at 4.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -1.9% surprise compares with a +7.0% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: lonvo-z (HAE)
- Concentration risk — Pipeline: nex-z (ATTR amyloidosis)
- Quality below floor (1.7 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.84
- Price target
- $21.55
- Stop
- $11.85
- Upside to target
- +67.8%
- Reward-to-risk
- 6.0:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
NTLA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.79B
- P/E (fwd)
- -4.9
- 52-week range
- $7.95–$28.25
- Off 52-week high
- 54.5%
- RSI (14)
- 56
- Volume vs avg
- 0.90×
- Score today
- 4.0/10